Interleukin-23 Subunit p19
"Interleukin-23 Subunit p19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subunit of interleukin-23. It combines with INTERLEUKIN-12 SUBUNIT P40, which is shared between the two cytokines, to form in the active interleukin-23 cytokine.
| Descriptor ID |
D053760
|
| MeSH Number(s) |
D12.644.276.374.465.759.500 D12.776.467.374.465.759.500 D23.529.374.465.550.500
|
| Concept/Terms |
Interleukin-23 Subunit p19- Interleukin-23 Subunit p19
- Interleukin 23 Subunit p19
- Interleukin-23 alpha Subunit
- Interleukin 23 alpha Subunit
- alpha Subunit, Interleukin-23
- IL-23p19
- IL-23 p19
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-23 Subunit p19".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-23 Subunit p19".
This graph shows the total number of publications written about "Interleukin-23 Subunit p19" by people in this website by year, and whether "Interleukin-23 Subunit p19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-23 Subunit p19" by people in Profiles.
-
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr; 82(4):936-945.
-
Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019 11; 11(16):1357-1370.
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
-
Distinct gene expression pathways in islets from individuals with short- and long-duration type 1 diabetes. Diabetes Obes Metab. 2018 08; 20(8):1859-1867.
-
Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol. 2006 Aug 01; 177(3):1416-20.
-
An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30.
-
IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol. 2005 Jul 15; 175(2):788-95.